Press coverage about CTI BioPharma (NASDAQ:CTIC) has trended somewhat positive on Sunday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CTI BioPharma earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.4823268640794 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several analysts have recently issued reports on the company. ValuEngine raised CTI BioPharma from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. Zacks Investment Research raised CTI BioPharma from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. Jefferies Financial Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of CTI BioPharma in a report on Friday, July 20th. BidaskClub cut CTI BioPharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 14th. Finally, JMP Securities set a $8.00 price objective on CTI BioPharma and gave the stock a “buy” rating in a report on Tuesday, July 10th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. CTI BioPharma has a consensus rating of “Buy” and a consensus target price of $5.83.

NASDAQ:CTIC traded down $0.13 during midday trading on Friday, hitting $1.95. 958,020 shares of the company traded hands, compared to its average volume of 1,065,382. CTI BioPharma has a 12-month low of $1.94 and a 12-month high of $5.36. The firm has a market capitalization of $120.62 million, a PE ratio of -1.57 and a beta of -0.32. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.30 and a current ratio of 4.28.

CTI BioPharma (NASDAQ:CTIC) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.03. CTI BioPharma had a negative return on equity of 90.92% and a negative net margin of 313.77%. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.30 million. equities analysts forecast that CTI BioPharma will post -0.6 EPS for the current year.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Recommended Story: Trading Penny Stocks

Insider Buying and Selling by Quarter for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with's FREE daily email newsletter.